The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases

Eker S. S., Sarandol A., Akkaya C., Sivrioglu E. Y., Kirli S.

JOURNAL OF PSYCHOPHARMACOLOGY, vol.23, no.8, pp.993-996, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 8
  • Publication Date: 2009
  • Doi Number: 10.1177/0269881108093843
  • Journal Name: JOURNAL OF PSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.993-996
  • Keywords: antipsychotic, QTc prolongation, ziprasidone, TORSADE-DE-POINTES, SCHIZOAFFECTIVE DISORDER, ANTIPSYCHOTIC-DRUGS, ACUTE EXACERBATION, DOUBLE-BLIND, 160 MG/DAY, SCHIZOPHRENIA, SAFETY, HALOPERIDOL, MANAGEMENT
  • Bursa Uludag University Affiliated: Yes

Abstract

QTc interval prolongation may appear as a consequence of both typical and atypical antipsychotic treatments. Ziprasidone, which is effective in treating schizophrenia, is associated with QTc prolongation. Although the prolongation of QTc with ziprasidone treatment is often pronounced, there is a scarce number of cases reported about the relationship between ziprasidone and QTc prolongation. Of the three cases presented in this case series, two cases showed values exceeding 0.50 s with ziprasidone treatment.